Резистентность H. pylori к антибактериальным препаратам и методы её определения | КМАХ

Резистентность H. pylori к антибактериальным препаратам и методы её определения

Клиническая Микробиология и Антимикробная Химиотерапия. 2010; 12(1):57-66

​ Исаева Г.Ш.
антибиотикорезистентность эффлюкс определение чувствительности
Раздел
Антибиотикорезистентность
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2010; 12(1):57-66

Аннотация

Во всем мире, в том числе в нашей стране, отмечена тенденция к распространению первичной, вторичной и множественной устойчивости H. pylori к антибактериальным препаратам, что значительно снижает эффективность противохеликобактерной терапии. Выявлены существенные различия в уровнях антибиотикорезистентности H. pylori в различных регионах России, что указывает на назревшую необходимость проведения многоцентровых исследований. Широкое внедрение молекулярно-генетических методов исследований в практических лабораториях позволит выявлять циркуляцию резистентных штаммов и динамику их распространения, оценивать результаты эрадикационной терапии и, возможно, в будущем определять группы больных с определёнными генотипами, определяющими резистентность к стандартным схемам противохеликобактерной терапии. В статье представлен обзор современных представлений о распространении антибиотико­резистентности Helicobacter pylori, её механизмах и методах определения чувствительности этого микроорганизма к антибактериальным препаратам.

  • 1. Mégraud F. Resistance of Helicobacter pylori to antibiotics. / In: Scarpignato C., Bianchi Porro G. Clinical pharmacoloy and therapy of Helicobacter pylori infection. Prog Basic Clin Pharmacol 1999; 11:329-45.
  • 2. Malfertheiner P., Megraud F., O’Morain C., et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2006; 10.
  • 3. Saidijam M., Benedetti G., Ren Q., et al. Microbial drug efflux proteins of the major facilitator superfamily. Curr Drug Targets 2006; 7:793-811.
  • 4. Dailidiene D., Bertoli M.T., Miciuleviciene J. Emergence of tetracycline resistance in: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother 2002; 46:3940-46.
  • 5. Li Y., Dannelly H.K. Inactivation of the putative tetracycline resistance gene HP1165 in Helicobacter pylori led to loss of inducible tetracycline resistance. Arch Microbiol 2006; 185:255-62.
  • 6. van Amsterdam K., Bart A., van der Ende A. Helicobacter pylori TolC efflux pump confers resistance to metronidazole. Antimicrob Agents Chemother 2005; 49:1477-82.
  • 7. Kutschke A., de Jonge B.L. Compound efflux in Helicobacter pylori. Antimicrob Agents Chemother 2005; 49:3009-10.
  • 8. Morrison S., Ward A., Hoyle C.J., Henderson P.J.F. Cloning, expression, purification and properties of a putative multidrug resistance efflux protein from Helicobacter pylori. Int J Antimicrob Agents 2003; 22:242-9.
  • 9. Bina J. E., Alm R.A., UriaNickelsen M., et al. Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob. Agents Chemother 2000; 44:248-54.
  • 10. DeLoney C.R., Schiller N.L. Characterization of an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44:3368-73.
  • 11. Stahler F.N., Odenbreit S., Haas R., et al. The novel Helicobacter pylori CznABC metal efflux pump is required for cadmium, zinc, and nickel resistance, urease modulation, and gastric colonization. Infect Immun 2006; 74:3845-52.
  • 12. Occhialini A., Urdaci M., Doucet-Populaire F., et al. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997; 41:2724-8.
  • 13. Meyer J.M., Silliman N.P., Wang W.J., et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori Antimicrobial Resistance partnership (SHARP) Study, 1993-1999. Ann Int Med 2002; 136:13-24.
  • 14. Duck W. M., Sobel J., Pruckler J. M., et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10:1088-94.
  • 15. Glupczynski Y., Megraud F., Lopez Brea M., Andersen L.P. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20:820-3.
  • 16. De Francesco V., Margiotta M., Zulla A., et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over 15 year period in Italy. J Antimicrob Chemother 2007; 59:783-5.
  • 17. Koletzko S., Richy F., Bontems P., et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006; 55:1711-6.
  • 18. Raymond J., Burucoa C., Pietrini O., et al. Clarithromycin resistance in Helicobacter pylori isolated from French children: prevalence of the different mutations and coexistence of clones harboring two different mutations in the same biopsy. Helicobacter 2007; (12):157-63.
  • 19. Кудрявцева Л.,В., Исаков В.А., Щербаков П.Л., Иваников И.О., Минаев В.И. Динамика резистентности штаммов Helicobacter pylori к антибиотикам у городского населения в России в 1996-1998 гг. В кн.: Helicobacter pylori: революция в гастроэнтерологии. Ивашкин В.Т., Мегро Ф., Лапина Т.Л. – М., Триада-Х,1999, с.191-6.
  • 20. Кудрявцева Л.В. Состояние антибиотикорезистентности Helicobacter pylori в России. Эксп и клин гастроэнтерол 2003; 3:7.
  • 21. Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374-84.
  • 22. Mendz G.L., Megraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 2002; 10:370-5.
  • 23. Marais A., Bilardi C., Cantet F., Mendz G.L., Megraud F. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol 2003; 154:137-44.
  • 24. Osato M.S., Reddy R., Reddy S. G., et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Int Med 2001; 161:1217-20.
  • 25. Perez Aldana L., Kato M., Nakagawa S., et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7:306-9.
  • 26. Nahar S., Mukhopadhyay A.K., Khan R., et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol 2004; 42:4856-8.
  • 27. Torres J., Camorlinga Ponce M., Perez Perez G., et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001; 39:2677-80.
  • 28. Heep M., Kist M., Strobel S., Beck D., Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19:538-41.
  • 29. Cederbrant G., Kahlmeter G., Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 1992; 29:115-20.
  • 30. Wheeldon T.U., Granstrom M., Hoang T.T.H., et al. Importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19:1315-21.
  • 31. Glupczynski Y., Broutet N., Cantagrel A., et al. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21:549-52.
  • 32. Gerrits M.M., van Villet A.H., Kuipers E.J., Kusters J.G. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6:699-709.
  • 33. Kim J.M., Kim J.S., Kim N., et al. Comparison of primary and secondary antimicrobial minimum inhibitory concentration for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006; 28:6-13.
  • 34. Gerrits M.M., Schuijffel D., van Zwet A.A., et al. Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46:2229-33.
  • 35. Dore M. P., Graham D.Y., Sepulveda A.R. Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Helicobacter 1999; 4:154-61.
  • 36. Mégraud F., Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clinical Microbiology Reviews 2007; 20:280-322.
  • 37. Nonaka L., Connell S.R., Taylor D.E. 16S rRNA mutations that confer tetracycline resistance in Helicobacter pylori decrease drug binding in Escherichia coli ribosomes. J Bacteriol 2005; 187:3708-12.
  • 38. Gerrits M.M., Berning M., Van Vliet A.H.M., Kuipers E.J., Kusters J.G. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47:2984-86.
  • 39. Wu J.Y., Kim J.J., Reddy R., et al. Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother 2005; 49:578-83.
  • 40. Midolo P.D., Korman M.G., Turnbridge J.D., et al. Helicobacter pylori resistance to tetracycline. Lancet 1996; 347:1194-5.
  • 41. Kim J. J., Reddy R., Lee M., et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001; 47:459-61.
  • 42. Tankovic J., Lascols C., Sculo Q., et al. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47:3942-4.
  • 43. Cabrita J., Oleastro M., Matos R., et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46:1029-31.
  • 44. Heep M., Rieger U., Beck D., Lehn N. Mutations in the beginning of the groB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44:1075-7.
  • 45. Heep M., Beck D., Bayerdorffer E., Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43:1497-9.
  • 46. Su Z., Xu H., Zhang C. et al. Mutations in Helicobacter pyloriporDand oorD genes may contribute to furazolidone resistance. Croat Medical 2006; 47:410-5.
  • 47. Лазебник Л.,Б., Морозов И.А., Ильиченко А.А., Хомерики С.Г. Проблемы и перспективы исследований инфекции Helicobacter pylori. Экс клин гастроэнтерол 2006; 2:4-14.
  • 48. Godoy A.P., Ribeiro M.L., Benvengo Y.H. et al. Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol 2003; 3:20.
  • 49. Пюрвеева К.В., Лапина Т.Л., Момыналиев К.Т. и соавт. Генотипирование в клинической практике ведения больных язвенной болезнью двенадцатиперстной кишки. Рос журнал гастроэнтерол, гепатолог, колопроктол 2003; 3(XIII):21-4.
  • 50. De Francesco V., Margiotta M., Zulla A., et al. Clarithromicyn resistance and Helicobacter pylori genotypes in Italy. J Microbiol 2006; 28:6-13.
  • 51. Mubarak S.А., Adeel Islam А., Abida A.Е. Analysis of Helicobacter pylori antimicrobial susceptibility and virulence genes in gastric mucosal biopsies in the United Arab Emirates. Indian J Gastroenterol 2007; 26:221-4.
  • 52. NCCLS. 1995. Performance standards for antimicrobial susceptibilities testing. M7-A3. National Committee for Clinical Laboratory Standards, Villanova, PA.
  • 53. Coudron P.E., Stratton C.W. Factors affecting growth and susceptibility testing of Helicobacter pylori in liquid media. J Clin Microbiol 1995; 33:1028-30.
  • 54. Hachem C.Y., Clarridge J.E., Reddy R., et al. Antimicrobial susceptibility testing of Helicobacter pylori: comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis 1996; 24:37-41.
  • 55. Piccolomini R., Di Bonaventura G., Catamo G., et al. Comparative evaluation of the E-test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 1997; 35:1842-6.
  • 56. Grignon B., Tankovic J., Megraud F., et al. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist 2002; 8:61-6.
  • 57. Versalovic J., Shortridge D., Kibler K., et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40:477-80.
  • 58. Ménard A., Santos A., Mйgraud F., Oleastrо M. PCRrestriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob Agents Chemother 2002; 46:1156-7.
  • 59. Gibson J.R., Saunders N.A., Burke B., Owen R.J. Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J Clin Microbiol 1999; 37:3746-8.
  • 60. Chisholm S.A., Owen R.J., Teare E.L., Saverymuttu S. PCR-based diagnosis of Helicobacter pylori infection and real-time determination of clarithromycin resistance directly from Helicobacter pylori human gastric biopsy samples. J Clin Microbiol 2001; 39:1217-20.
  • 61. Schabereiter-Gurtner C., Hirschl A.M., Dragosics B., et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol 2004; 42:4512-8.
  • 62. Lottspeich C., Schwarzer A., Panthel K. Koletzko S., Russmann H. Evaluation of the novel H.pylori ClariRes Real-Time PCR Assay for detection and clarithromycin susceptibility testing of Helicobacter pylori in stool specimens from symptomatic children. J Clin Microbiol 2007; 45:1718-22.
  • 63. Glocker E., Kist M. Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J Clin Microbiol 2004; 42:2241-6.
  • 64. Nishizawa T., Suzuki H., Umezawa A., et al. Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J Clin Microbiol 2007; 45:303-5.
  • 65. Ribeiro M.L., Gerrits M. M., Benvengo Y.H.B., et al. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol Med Microbiol 2004; 40:57-61.
  • 66. Trebesius K., Panthel K., Strobel S., et al. Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut 2000; 46:608-14.
  • 67. Samarbaf-Zadeh A.R., Tajbakhsh S., Moosavian S.M., et al. Application of fluorescent in situ hybridization (FISH) for the detection of Helicobacter pylori. Med Sci Monit 2006; 12:426-30.
  • 68. Yilmaz O., Demiray E., Tьmer S., et al. Detection of Helicobacter pylori and determination of clarithromycin susceptibility using formalin-fixed, paraffin-embedded gastric biopsy specimens by fluorescence in situ hybridization. Helicobacter 2007; 12:136-41.
  • 69. Latham S.R., Labigne A., Jenks P.J. Production of the RdxA protein in metronidazole-susceptible and – resistant isolates of Helicobacter pylori cultured from treated mice. J Antimicrob Chemother 2002; 49:675-8.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились